Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase NA 1Phase 1 1

Status

Completed 64Recruiting 52Terminated 29Withdrawn 18Unknown 15Active not recruiting 15Not yet recruiting 14Suspended 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 3Drug Therapy 3Vincristine 2S 1 (combination) 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2CA-4948 2Bevacizumab 2zimberelimab 1venetoclax 1tivozanib 1titanium silicide 1tisagenlecleucel 1sotigalimab 1propranolol CR 1prednylidene 1pimonidazole 1palbociclib 1mirdametinib 1imisopasem manganese 1gusacitinib 1fludarabine 1deltacortene 1brincidofovir 1axicabtagene ciloleucel 1atezolizumab 1Testosterone Propionate 1Testosterone 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Bevacizumab × Clear all
NCT01386710 2025-04-09

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Northwell Health

Phase 1/2 Suspended
54 enrolled
CNS

Astrocytoma, Glioblastoma, Neoplasms

NCT01933815 2023-02-22

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Cortice Biosciences, Inc.

Phase 1/2 Suspended
92 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡